Claims for Patent: 10,016,377

Summary for Patent: 10,016,377

Title:	Treatment of hepatitis C using histone deacetylase inhibitors
Abstract:	The present invention relates to method of treatment of hepatitis C using bufexamac or a derivative thereof. The methods of the present invention can be used in patients with hepatitis C administering bufexamac or a derivative thereof in combination with one or more anti-hepatitis C drugs.
Inventor(s):	Malhotra; Geena (Mumbai, IN), Joshi; Kalpana (Maharashtra, IN)
Assignee:	Cipla Limited (Mumbia, IN)
Application Number:	15/684,192
Patent Claims:	1. A kit comprising an anti-hepatitis C effective amount of a compound of Formula I: ##STR00003## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is selected from hydrogen, C(O)R, C(O)OR, C(O)NR.sub.2R.sub.3, and PO.sub.3X.sub.2; R.sup.2 is selected from hydrogen, C(O)R, C(O)OR, C(O)NR.sub.3R.sub.4, and PO.sub.3X.sub.2; X is independently selected from hydrogen, pharmaceutically acceptable cation, or R; wherein R, R.sup.3 and R.sup.4 are in each case independently selected from hydrogen, optionally substituted C.sub.1-8alkyl, optionally substituted C.sub.6C.sub.12aryl, optionally substituted C.sub.3-8cycloalkyl, optionally substituted C.sub.2-12heterocyclyl, or optionally substituted C.sub.2-12heteroaryl; and at least one other anti-hepatitis C drug. 2. The kit of claim 1, wherein R.sup.1 and R.sup.2 are each hydrogen. 3. The kit of claim 1, wherein the one or more anti-hepatitis C drugs comprises recombinant Human Interferon Alfa (peginterferon), nucleoside analogs, direct acting antivirals, NS3/4A protease inhibitors, nucleotide NS5B polymerase inhibitors, NS5A inhibitors, non-nucleoside NS5B polymerase inhibitors, or a combination thereof. 4. The kit of claim 1, wherein the one or more anti-hepatitis drugs comprises pegylated interferon alfa-2a, pegylated interferon alfa-2b, ribavirin, daclatasvir, boceprevir, telapravir, simeprevir, sofosbuvir, daclatasvir, dasabuvir, ledipasivir, velpatasvir, paritaprevir, ombitasvir, elbasvir, grazoprevir, asunaprevir, beclabuvir, or a combination thereof. 5. The kit of claim 1, comprising a pharmaceutical composition comprising the compound of Formula I in an amount from 10-500 mg. 6. The kit of claim 5, wherein the composition comprising the compound of Formula I also comprises the at least one other anti-hepatitis C drug. 7. The kit of claim 1, comprising a first pharmaceutical composition comprising the compound of Formula I, and at least one other pharmaceutical composition comprising at least one other anti-hepatitis C drug.

Details for Patent 10,016,377

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2035-12-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2035-12-09
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2035-12-09
Hoffmann-la Roche Inc.	ROFERON-A	interferon alfa-2a	For Injection	103145	06/04/1986		2035-12-09